LEXICON
No.93 December 5, 2011

Drug cost ratio
薬剤費比率
National healthcare expenditure
国民医療費
Wards for recuperation under health insurance
医療(保険型)療養病棟
Wards for recuperation under nursing care insurance
介護(保険型)療養病棟
Ward charging special admission fee
特定入院料算定病棟
Ward for rehabilitation during convalescence
回復期リハビリテーション病棟

The drug cost ratio (薬剤費比率) is defined as the cost of drugs (薬剤費) used under the health insurance system (医療保険制度) as a percentage of national healthcare expenditure (国民医療費). As a rule, each ethical drug (医療用医薬品) is reimbursed at its NHI...

To read the full story

LEXICON

By Shinya Sato

Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…

By Philip Carrigan

It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…

A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…

The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…